Lung Rejuvenation Protocol

An integrative, physician-designed approach for adults with chronic lung dysfunction — COPD, post-COVID lung damage, fibrosis, post-TB scarring — and those exposed to high pollution, living with smokers, or experiencing recurrent respiratory infections.

At a Glance

What it targets: The drivers of chronic lung dysfunction — ongoing oxidative-inflammatory damage, mitochondrial decline, impaired tissue repair, and the systemic effects of chronic respiratory disease.

Who it’s for: Adults with COPD, post-COVID lung fibrosis, IPF, ILD, post-TB damage, bronchiectasis, or chronic bronchitis under pulmonology care. Also for those exposed to high pollution, living with smokers, or with recurrent URTIs.

How it works: Physician-supervised workup, anti-inflammatory and mitochondrial support, systemic regenerative IV therapies, and — in selected cases — ALIV’s PRP for Lung Rejuvenation or autologous cell therapy.

What to expect: Inflammatory burden, exercise tolerance, and quality of life often shift in early and building phases. Lung function changes are slower, more variable, and depend on disease type and stage. ALIV does not guarantee lung function improvement or disease reversal.

Who This Protocol Is For

India carries one of the world’s heaviest chronic lung disease burdens. Many clients arrive specifically researching COPD treatment, pulmonary fibrosis treatment, post-COVID lung damage, PRP for lungs, or how to improve lung function in India — and want an integrative approach alongside their pulmonologist. A 2021 Indian SR/MA estimated COPD prevalence around 7% in adults over 30, higher in older populations exposed to biomass smoke, occupational dusts, or smoking. A 2022 multicentre Indian ILD registry found sarcoidosis, CTD-ILD, and hypersensitivity pneumonitis as the most common subtypes. Post-COVID lung changes affect many recovered patients, and post-TB damage is a lifelong reality for many.

Standard pulmonology does its job well: bronchodilators and inhaled steroids for COPD, anti-fibrotic therapy (pirfenidone, nintedanib) for IPF, oxygen where needed, surgical and bronchoscopic options where appropriate. What it often does not have time for is the upstream layer — inflammation, oxidative stress, mitochondrial function, immune resilience, and lifestyle inputs that determine trajectory.

This protocol was built for you if:

• You have diagnosed COPD, IPF, ILD, post-TB lung damage, bronchiectasis, or chronic bronchitis
• You have post-COVID lung fibrosis or persistent respiratory symptoms unresolved by time alone
• You’re a long-term smoker who has quit and want to support residual lung repair
• You live with a smoker and are exposed to second-hand smoke — the lung injury risk is real
• You live or work in high-pollution conditions (urban PM2.5, occupational dust, biomass smoke)
• You experience recurrent upper respiratory tract infections and want to strengthen immune resilience

Important: This protocol is integrative, not alternative. ALIV does not support reducing or discontinuing pulmonologist-prescribed medications. Your pulmonologist remains the primary clinician for your lung disease.

How It Works — The ALIV Approach

Chronic lung disease is multi-system: oxidative-inflammatory damage to lung tissue, mitochondrial dysfunction in lung and skeletal muscle, impaired regenerative capacity, systemic effects on energy and cardiovascular function. The protocol addresses each.

Layer 1 — Workup and Diagnostic Precision

Before any intervention, your ALIV physician runs a workup that complements your pulmonology assessment: metabolic and inflammatory panel (hsCRP, ESR, ferritin), micronutrient status, mitochondrial markers, recent pulmonary function tests and HRCT review, oxygen saturation, exercise tolerance, and skeletal muscle assessment. The protocol is shaped by what this reveals.

Layer 2 — Anti-Inflammatory, Antioxidant, and Mitochondrial Foundation

Chronic lung disease is fundamentally an oxidative-inflammatory state with mitochondrial dysfunction — in lung tissue, skeletal muscle, and systemically. Cigarette smoke, biomass smoke, second-hand smoke, and particulate pollution drive free radical injury overwhelming endogenous defences. Targeted intervention with NAC, glutathione, Vitamin D, Omega-3, Vitamin C, magnesium, CoQ10/Ubiquinol reduces damage. NAC has the strongest COPD evidence — mucolytic, antioxidant, and exacerbation-reducing. For clients with recurrent URTIs, Thymosin Alpha-1 is added as an immune modulator to reduce infection frequency.

Layer 3 — Systemic Regenerative Support

Where appropriate, broader regenerative support is integrated: ALIV’s NAD+ Vitality IV for cellular energy and mitochondrial function, Immune Defence IV during infection windows, and coordination with the Energy Restoration Protocol for the fatigue and deconditioning that accompany chronic lung disease.

Layer 4 — PRP for Lung Rejuvenation (If and When Indicated)

ALIV offers PRP for Lung Rejuvenation as a specialty therapy in selected cases. Biological rationale: platelet growth factors (PDGF, VEGF, TGF-β, EGF) support tissue repair, modulate inflammation, and may stimulate regenerative pathways. Honest framing: evidence is preliminary. A 2023 narrative review of 15 studies found PRP in chronic respiratory disease produced anti-inflammatory effects and signs of tissue regeneration; larger controlled trials are needed. Not FDA-approved. Suitability case-by-case with your pulmonologist.

Layer 5 — Autologous Cell Therapy (If and When Indicated)

For advanced cases where PRP and the broader protocol are insufficient, ALIV’s autologous cell therapy pathway can be considered. Investigational; reserved for selected clients after workup, upstream optimisation, and pulmonology coordination. Evidence is early; outcomes not guaranteed.

What to Expect

Chronic lung disease produces structural changes that are sometimes partially reversible, sometimes stable, sometimes progressive. The protocol aims to slow progression, improve quality of life, support residual repair, and address systemic impacts — not to guarantee lung function gains.

Outcomes vary substantially based on disease type, severity, duration, ongoing exposures, and adherence. ALIV does not guarantee lung function improvement, disease reversal, or specific clinical outcomes.

What’s Involved

Before starting, your ALIV team runs the diagnostic assessment, reviews your pulmonology workup, and — with your permission — coordinates with your pulmonologist. Contraindications detailed in the FAQ below.

The Lifestyle Layer

Lifestyle and environmental inputs determine the difference between progressive deterioration and stable disease.

Smoking cessation — the single most important intervention: if you smoke and have any chronic lung disease, cessation is the highest-leverage intervention available. Continued smoking guarantees progression and undermines every other intervention. ALIV provides cessation support but does not initiate regenerative layers in active smokers.

Air quality, pulmonary rehab, nutrition, sleep: PM2.5 is a major lung disease driver in Indian urban contexts — HEPA filtration at home, N95 masks on high-pollution days, exposure reduction, avoidance of biomass smoke and incense. Pulmonary rehabilitation is one of the most evidence-supported interventions and ALIV strongly recommends it alongside this protocol. Nutrition: adequate protein for respiratory muscle, anti-inflammatory patterns. Sleep: OSA is under-recognised in COPD patients and significantly worsens outcomes.

Infection prevention: annual influenza vaccination, pneumococcal vaccination per guidelines, updated COVID-19 vaccination, exposure reduction during respiratory virus seasons.

Frequently Asked Questions

Will this replace my inhalers, oxygen, or anti-fibrotic medication?

No. Pulmonologist-prescribed medications — bronchodilators, inhaled steroids, oxygen, anti-fibrotics — remain the foundation. ALIV provides the integrative layer.

How can I improve my lung function naturally?

Biggest natural levers: stop smoking (and avoid second-hand smoke); reduce particulate exposure (HEPA filtration, N95 masks on bad air days, avoid biomass smoke); build aerobic capacity through pulmonary rehabilitation and graded exercise; adequate protein for respiratory muscle; manage OSA; vaccinate against respiratory infections. Where structural damage exists, natural measures slow progression but don’t replace medical or regenerative intervention.

Does PRP for the lungs actually work?

Evidence is preliminary and accumulating. Biological rationale is strong; reported effects on inflammation, exacerbations, and quality of life are encouraging; larger controlled trials are needed. PRP for Lung Rejuvenation is a regenerative adjunct, not a guaranteed therapy.

Can lung damage be reversed?

Depends on type and stage. Established structural emphysema, advanced fibrosis, and severe bronchiectatic changes are typically not fully reversible. Earlier disease, post-COVID changes, and inflammatory components have more reversal potential.

How is this different from pulmonary rehabilitation?

Pulmonary rehab is critical and well-evidenced — ALIV strongly recommends it alongside this protocol. The ALIV protocol adds regenerative, anti-inflammatory, and mitochondrial layers pulmonary rehab does not provide.

I’m post-COVID with lung scarring — is it too late?

Often, no. Post-COVID lung changes have substantial reversal potential, especially within the first 6-18 months. Coordinates with Post-COVID / Long COVID Recovery.

Who should NOT do this protocol?

Severe oxygen-dependent respiratory failure or active acute exacerbation; end-stage disease requiring transplant evaluation; active smokers (regenerative layers not initiated until cessation); clients seeking to bypass pulmonology care.

Take the Next Step

Chronic lung disease is one of the most disabling and under-treated conditions in Indian medicine. This protocol adds the regenerative, anti-inflammatory, and immune-support layer conventional pulmonology does not manage.

To find out if the Lung Rejuvenation Protocol is right for you, speak with our medical team:

• Pune (Bund Garden): +91 77199 88811
• Mumbai (Khar West): +91 98220 93069

Or book a consultation through alivtherapy.in.

Research References

1. Daniel RA, Aggarwal P, Kalaivani M, Gupta SK. Prevalence of chronic obstructive pulmonary disease in India: a systematic review and meta-analysis. Lung India. 2021;38(6):506-513. DOI: 10.4103/lungindia.lungindia_159_21

2. Dhooria S, Sehgal IS, Agarwal R, Muthu V, Prasad KT, Kathirvel S, et al. Incidence, prevalence, and national burden of interstitial lung diseases in India: estimates from two studies of 3089 subjects. PLoS One. 2022;17(7):e0271665. PMID: 35862355

3. Knight AD, Kacker S. Platelet-Rich Plasma Treatment for Chronic Respiratory Disease. Cureus. 2023;15(1):e33265. DOI: 10.7759/cureus.33265

4. McDonough JE, Yuan R, Suzuki M, et al. Small-airway obstruction and emphysema in chronic obstructive pulmonary disease. N Engl J Med. 2011;365(17):1567-1575. PMID: 22029978

5. Singh AK, Bhushan B, Singh S, et al. Long COVID in India: a prospective multicenter observational cohort study. Indian J Med Res. 2025 (Singh 2025 LC India cohort) — cross-reference Post-COVID / Long COVID Recovery Protocol.

Disclaimer

The information on this page is for educational purposes only and is not intended as medical advice. ALIV therapies are not intended to diagnose, treat, cure, or prevent any disease, including COPD, IPF, post-COVID lung fibrosis, interstitial lung disease, post-tuberculosis lung damage, or any other chronic respiratory condition. This protocol is integrative supportive care provided alongside — not as a replacement for — specialist pulmonology management. Outcomes vary significantly; ALIV does not guarantee lung function improvement, disease reversal, or any specific clinical outcome. PRP for Lung Rejuvenation Therapy and autologous cell therapy are investigational regenerative options; evidence is early-to-preliminary and they are not FDA-approved. Both are reserved for selected cases after physician assessment and pulmonology coordination. Anti-fibrotic medications (pirfenidone, nintedanib), bronchodilators, inhaled steroids, oxygen therapy, and other pulmonologist-prescribed treatments must be continued as directed. Please consult a qualified healthcare professional before starting any therapy programme.